ENGN
enGene Holdings Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.82
−0.55%Jul 16, 2026, 00:00 UTC
Richard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.
Jun 15, 2026, 14:00 UTC
enGene Therapeutics Inc. reported its financial results for the second quarter of fiscal year 2026.
Source:Jun 15, 2026, 00:00 UTC
enGene Therapeutics Inc. announced the resignation of Chief Medical Officer Hussein Sweiti effective June 14, 2026, and the termination of Chief Financial Officer Ryan Daws and Chief Legal Officer Lee Giguere effective July 15, 2026.